AMETEK INC/ Q4 FY2024 earnings call

Management Statement and Operational Highlights

• AMETEK delivered strong fourth quarter results with records in sales, operating income, EBITDA, diluted earnings per share, operating cash flow, and free cash flow.
• Repurchased $155 million in shares during the quarter and announced the acquisition of Kern Microtechnik for approximately €105 million.
• In 2024, established annual records for key financial metrics, with overall sales at $6.940 billion, up 5% from 2023. Operating income was $1.81 billion, up 6%, and EBITDA was $2.18 billion, up 8%.
• Invested approximately $90 million in incremental growth investments in 2024 and expect to invest ~$85 million in 2025, focusing on R&D, engineering, sales, and marketing.
• Highlighted innovation successes like CAMECA's LEAP 6000XR atom probe microscope, which broadened market applications.

Segment Performance

• Electronic Instruments Group (EIG): Fourth quarter sales were a record $1.2 billion, down 2% from the prior year. Organic sales were down 3% while acquisitions added 1 point. Operating income was a record $386.6 million, up 8% versus the prior year, with operating margins also a record 31.8%, up 280 basis points from the prior year.
• Electromechanical Group (EMG): Fourth quarter sales were $540 million, with organic sales down 4%. Operating income in the fourth quarter was $111.2 million, down 1% compared to the prior year period, while EMG's fourth quarter operating margins were 20.3%.

Guidance

• For 2025, overall and organic sales are expected to increase low single digits compared to 2024.
• Diluted earnings per share for 2025 are expected to be in the range of $7.02 to $7.18, up 3% to 5% compared to 2024.
• First quarter 2025 sales are anticipated to be roughly flat versus the prior year first quarter, with adjusted earnings of $1.67 to $1.69 per share, up 2% to 3% versus the prior year.

Risks

• Macroscopic uncertainties affecting the economic environment.
• Trade uncertainties, including potential tariffs and their impact on supply chains and costs.
• Ongoing OEM destocking headwinds impacting EMG's OEM exposed businesses.

Q: Talk about the nature of delays in EIG and the remaining duration of OEM destocking in EMG.

A: Project delays in EIG were across the board with shipment delays but good orders. In EMG, OEM destocking headwinds impacted certain sub-segments, with improved order patterns from some OEM customers but some still destocking.

Q: Discuss price cost in 2024, views for 2025, and price capture.

A: In 2024, price cost was in line, and for 2025, expected to offset increased price with inflation, targeting a 1.5% to 2% pricing range.

Q: Update on Paragon's revenue base and margin improvement.

A: Paragon was around $420 million in 2024 revenues, expecting growth higher than AMETEK in 2025 with substantial margin improvement, well in excess of company-wide margins.

Q: Cadence of orders, macroeconomic concerns, and guidance.

A: Orders increased every month of the quarter, with December and January showing positive orders, and guidance considering conservative start to the year with pipelines and destocking easing.

Q: Project timing, ES backlog conversion, and Aerospace and Defense outlook.

A: Projects delayed are moving, ES backlog conversion tied to destocking abatement, with Aerospace and Defense expected to grow mid-single digits in 2025 with strength in commercial and defense markets.

Q: Margin performance, government policy impact on demand, and FX impact.

A: Margin performance due to operational excellence, no specific harm to laboratory demand with positive regulatory and policy outlooks, and FX not overly impacting top line due to balanced footprint.

Q: Organic growth in Q1 guidance, tariff impact, and portfolio divestitures.

A: Q1 organic growth flat, prepared for tariffs with supply chain decoupling and flexibility, and no substantial divestiture plans impacting guidance.

Q: Growth investments split, vitality index, and new product intros.

A: Growth investments largely in RD&E, vitality index around 20%-30% (high in Q4 30%), excited about new products from strong innovation pipeline.